News | November 11, 2022
Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The company is making its entry into the Hyderabad market through its unique asset-light business model
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
The team will assist the State Health Authorities in instituting public health measures and facilitate operationalization of requisite control and containment measures
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
Subscribe To Our Newsletter & Stay Updated
